Stockscreener 앱 받기
0.7034
4.70%
-0.0347
시간 외 거래:
.70
-0.0034
-0.48%
Mustang Bio Inc 주식(MBIO)의 최신 뉴스
CNET Q3 2011 Earnings: EPS Misses by 65.4% Amid Uncertain Revenue DisclosureEarnings Growth Analysis - newsline.com
MBIO Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
ADXN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
CCL Q1 2026 Earnings: EPS Surpasses Estimates by 7.3%, Shares Gain 2.5%Cash Flow Report - newsline.com
MBIO Should I Buy - Intellectia AI
Spring Valley Acquisition Corp. III (SVAC) Holds Near Support Amid Modest DeclineRTH Profile - newsline.com
Mustang Bio (MBIO) Moves Higher, Testing Key Resistance at $0.83Analyst Downgrade Signals - newsline.com
Water Utility Fined £1.8 Million Over Parasite Outbreak in DevonProfit Announcement - newsline.com
JATT Price Today: JATT II Acquisition Corp. Stock Price, Quote & Chart | MEXC - MEXC
Mustang Bio Q4 2024 Earnings: Massive EPS Miss Highlights Cash Burn and Clinical Progress UncertaintyCapex Guidance - newsline.com
MSN Money - MSN
Mustang Bio (MBIO) Q4 2024 Earnings: Wider-Than-Expected Losses Offset by Positive Stock Movement Amid Pipeline FocusGuidance Accuracy Score - newsline.com
WaFd Inc. (WAFD) Q1 2026 Earnings: EPS Tops Estimates; Small Decline in StockFree Cash Flow Trends - The Legal Advocate
Real Asset Acquisition Corp. Unit (RAAQU) Holds Steady Near Support as Consolidation Phase ContinuesInvestment Factor - The Legal Advocate
Is Mustang Bio (MBIO) a Hidden Gem in the Microbiome Revolution, or a Risky Bet - Kavout
Mustang Bio Inc. (MBIO) Q4 2024 Earnings: Wider-than-Expected Loss Amid Pre-Revenue StageEarnings Miss Alert - newsline.com
Mustang Bio Inc. (MBIO) Gains 5.68% as Shares Approach Key Resistance at $0.70Merger Arbitrage - The Legal Advocate
Mustang Bio Inc. (MBIO) Q4 2024 Earnings: Severe EPS Miss Highlights Pre-Revenue Biotech Challenges - The Legal Advocate
Mustang Bio Inc. (MBIO) Q4 2024 Earnings: Massive EPS Miss Amidst No RevenueTangible Book Value - newsline.com
Mustang Bio (MBIO) Edges Higher: Biotech Stock Testing Key Resistance at $0.67Wyckoff Distribution - newsline.com
Varonis Systems (VRNS) Holds Steady Amid Minor Dip; Key Levels in FocusHull Moving Average - The Legal Advocate
SKYX Platforms Stock Slides: Support Test at $1.05 as Bearish Pressure MountsIV Rank - newsline.com
OSBC Q1 2026 Earnings: Earnings Miss Estimates Amid Narrowing MarginsTrough Earnings Signal - newsline.com
Universal Corporation (UVV) Q1 2026 Results Miss Estimates — EPS $1.32 vs $1.94Weak Earnings Momentum - The Legal Advocate
Mustang Bio (MBIO) Slides -1.27% as Selling Pressure Mounts 2026-05-18AI Expert Picks - Newser
What Mustang Bio (MBIO)'s -0.88% Decline Means for Investors 2026-05-18Stock Analysis Community - Newser
Mustang Bio stock (US62815P1003): restructuring progress keeps spotlight on cash and pipeline - AD HOC NEWS
Mustang Bio stock (US62815P1003): restructuring moves and Nasdaq relisting plan put focus back on ce - AD HOC NEWS
Brigade Enterprises FY26 Pre-Sales Dip 5% to Rs 7,424 Crore on Approval Delays; Board Recommends 1:3 Bonus IssueEarnings Outlook Update - The Legal Advocate
Mustang Bio’s Cancer Therapy Bets Face A Nasdaq Countdown - Finimize
TradingKey - TradingKey
Mustang Bio (NASDAQ: MBIO) reports Q1 loss, limited cash and Nasdaq bid-price risk - Stock Titan
Mustang Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
What Booz Allen (BAH) is doing to win in its industry | Q1 2026: EPS Tops ViewsConsensus Beat Rate - The Legal Advocate
SERA (Sera Prognostics) tops Q4 2025 EPS estimates, shares fall 2.51% on lack of revenue visibility.GAAP Earnings Report - The Legal Advocate
MUSTANG BIO, INC. (MBIO) - MSN
CAR-T Cell Therapy Market Will Generate Booming Growth Opportunities to 2030 | Novartis, Johnson & Johnson Services, Mustang, Sorrento Therapeutics, Fate Therapeutics etc. - industrytoday.co.uk
1.27%
1.43%
자본화:
|
볼륨(24시간):